Home > Publications database > Commentary on Folkman: 'How Is Blood Vessel Growth Regulated in Normal and Neoplastic Tissue?'. > print

001     125453
005     20240228143308.0
024 7 _ |a 10.1158/0008-5472.CAN-16-1123
|2 doi
024 7 _ |a pmid:27197228
|2 pmid
024 7 _ |a 0008-5472
|2 ISSN
024 7 _ |a 0099-7013
|2 ISSN
024 7 _ |a 0099-7374
|2 ISSN
024 7 _ |a 1538-7445
|2 ISSN
024 7 _ |a altmetric:7372514
|2 altmetric
037 _ _ |a DKFZ-2017-01582
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Augustin, Hellmut
|0 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b
|b 0
|e Last author
|u dkfz
245 _ _ |a Commentary on Folkman: 'How Is Blood Vessel Growth Regulated in Normal and Neoplastic Tissue?'.
260 _ _ |a Philadelphia, Pa.
|c 2016
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1521117558_30678
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Angiogenesis is a prerequisite for tumor growth and metastatic progression. The discovery of the first specific angiogenic cytokine, VEGF, in 1989 paved the way for the clinical approval of the first antiangiogenic tumor drug 15 years later. This brief commentary highlights and puts into historical perspective the 1985 G.H.A. Clowes Memorial Award Lecture delivered by Dr. Judah Folkman. Thirty years later, this award lecture is a lively testimony of the visionary mind of Dr. Folkman, whose legacy continues to inspire contemporary angiogenesis research. Cancer Res; 76(10); 2854-6. ©2016 AACRSee related article by Folkman J, Cancer Res 1986;46:467-73.
536 _ _ |a 311 - Signalling pathways, cell and tumor biology (POF3-311)
|0 G:(DE-HGF)POF3-311
|c POF3-311
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Angiogenesis Inhibitors
|2 NLM Chemicals
773 _ _ |a 10.1158/0008-5472.CAN-16-1123
|g Vol. 76, no. 10, p. 2854 - 2856
|0 PERI:(DE-600)2036785-5
|n 10
|p 2854 - 2856
|t Cancer research
|v 76
|y 2016
|x 1538-7445
909 C O |o oai:inrepo02.dkfz.de:125453
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-311
|2 G:(DE-HGF)POF3-300
|v Signalling pathways, cell and tumor biology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2016
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER RES : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCER RES : 2015
920 1 _ |0 I:(DE-He78)A190-20160331
|k A190
|l Vaskuläre Onkologie und Metastasierung
|x 0
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A190-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21